A Gene-Based Prognostic for Hepatocellular Carcinoma Patient Response to Adjuvant Transcatheter Arterial Chemoembolization

Hepatocellular Carcinoma (HCC) is one of the most common cancers worldwide with largely unfavorable outcomes due to a lack of effective treatment options for patients in the later state of disease. The gold standard of care for HCC patients with intermediate to locally advanced tumors is transcatheter arterial chemoembolization (TACE), a procedure whereby the tumor is targeted both with local chemotherapy and restriction of local blood supply. TACE procedures are often not effective however, and a need exists to identify patients that will respond to TACE.

NCI scientists have identified a 14-gene signature predictive of response to TACE. This “TACE Navigator Gene Signature Assay” based on a Nanostring platform, is useful in identifying HCC patients in advance who will respond to and have the greatest survival benefit following TACE, and can identify patients who need additional/alternative therapeutic modalities.


Potential Commercial Applications: Competitive Advantages:
  • Prognostic test for HCC patient response to TACE procedure
  • Companion diagnostic for TACE procedure
  • First in class prognostic diagnostic for frontline therapy in highly prevalent HCC

Development Stage:
Basic (Target Identification)

Related Invention(s):


Xin Wang (NCI)  ➽ more inventions...

Valerie Miller (NCI)  ➽ more inventions...

Intellectual Property:
US Provisional Application No. 62/292,789
China Application No. PCT/US2017/016851
European Patent Application No. 201780018693.9
US Application No. 17706618.0
Application No. 16/076,239

Collaboration Opportunity:

Licensing and research collaboration

Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-101-2016
Updated: Jan 8, 2019